北京热景生物技术股份有限公司关于以集中竞价交易方式回购股份方案的公告

Core Points - The company plans to repurchase shares with a total fund amounting to no less than RMB 100 million and no more than RMB 200 million [2] - The maximum repurchase price is set at RMB 244.00 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [3] - The repurchased shares will be used for employee stock ownership plans or equity incentives [7][17] Summary by Sections Repurchase Plan Overview - The repurchase will be conducted through centralized bidding on the Shanghai Stock Exchange [9] - The duration for the repurchase is set for 12 months from the board's approval date [10] - The funding for the repurchase will come from the company's own funds [12] Board Meeting and Approval - The board meeting to approve the repurchase plan was held on November 11, 2025, with all seven directors present, resulting in unanimous approval [6][28] - The repurchase plan does not require shareholder approval as per the company's articles of association [6] Shareholder Information - Current major shareholders, including directors and executives, do not have any clear plans for share reduction in the next three to six months [4][16] - The controlling shareholder, Lin Changqing, has reduced his holdings by 1,000,000 shares, representing 1.0787% of the total share capital [24] Financial Impact - As of September 30, 2025, the company's total assets were RMB 3.2078 billion, and the equity attributable to shareholders was RMB 2.9328 billion. The maximum repurchase amount of RMB 200 million would account for approximately 6.23% and 6.82% of these figures, respectively [13]